VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

About this update from Vivosim Labs, Inc.

VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced that data demonstrating the power of its advanced 3D human tissue models will be featured in two presentations at the European Society of Toxicology's annual conference. The presentations collectively showcase the best-in-industry predictive power of VivoSim's proprietary AI-enabled NAMkind™ Liver and NAMkind™ GI platforms. In liver toxicology testing, across a set of compounds where animal models and traditional methods provide 50-65% sensitivity, VivoSim's models provided >90% sensitivity at detecting true positives for liver toxicity. Whereas current methodologies including animal in vivo testing can result in >10% false positives (wrongly predicted to have liver tox when they do not, causing rejection of a viable drug candidate), VivoSim's liver toxicology methods result in fewer than 5% false positives. These powerful results help VivoSim clients avoid expensive mistakes in drug development, at a time when the industry is undergoing a shift in preclinical safety evaluation. "With a heavy push from the US FDA, the pharmaceutical industry is moving away from traditional animal testing toward high-fidelity, human-relevant alternatives," said Keith Murphy, VivoSim Executive Chairman. "As our newest data show, using AI-informed models in highly accurate tissues, we detect the problems that pharma typically misses. When a pharma has a miss, the cost to them is many lost years and $50M - $200M, so strategic-thinking pharma executives are taking notice of the availability of better tools." The United States Food and Drug Administration (FDA) is actively encouraging human-relevant NAMs in place of animal studies, a push that is resulting in greater pharma demand for new technologies. After presenting its April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies, the FDA recently reported that it is meeting its goals for stimulating pharma uptake of these new models. VivoSim's novel models offer perhaps the most predictive tool to make FDA's vision a reality. VivoSim'...

View stock analysis, news, and events for Vivosim Labs, Inc.